Hua Shan Biography and Net Worth

Director of Cerus

Hua Shan, MD, PhD has served as a member of our Board since July 2022. Since April 2015, Dr. Shan has served as a Professor and Medical Director of Transfusion Medicine Services at Stanford University Medical Center. Previously, beginning in 1998, Dr. Shan practiced transfusion medicine at Johns Hopkins Medical Institutions. Dr. Shan is a leading expert on international transfusion practice and blood transfusion safety. She has led several large education and research programs on blood availability, blood safety and effective clinical transfusion practice. Dr. Shan directed Johns Hopkins University’s U.S. National Institutes of Health Fogarty International Blood Safety Program from 2000 to 2008. From 2006 to 2011, she was the Principal Investigator for the National Heart, Lung and Blood Institute (NHLBI) sponsored Retroviral Epidemiology Donor Study (REDS–II) International China Program. Since 2011, Dr. Shan served as the Principal Investigator for NHLBI’s Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) International-China Program. Dr. Shan is a member of editorial boards of several leading international journals including Transfusion and Transfusion Medicine Review. Dr. Shan is a member of the ISBT’s Transfusion-Transmitted Infectious Diseases Working Party and AABB’s Clinical Transfusion Medicine Committee. Dr. Shan has contributed to over one hundred publications in the field of blood transfusion practice. Dr. Shan received residency and fellowship training at the Hospital of University of Pennsylvania. She is a graduate of Peking University School of Medicine and holds a Ph.D. in immunology from University of Pennsylvania.

What is Hua Shan's net worth?: The estimated net worth of Hua Shan is at least $68.01 thousand as of May 13th, 2024. Dr. Shan owns 32,386 shares of Cerus stock worth more than $68,011 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Shan may own. Learn More about Hua Shan's net worth.
How do I contact Hua Shan?: The corporate mailing address for Dr. Shan and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Hua Shan's contact information.
Has Hua Shan been buying or selling shares of Cerus?: Hua Shan has not been actively trading shares of Cerus during the last ninety days. Most recently, on Monday, May 13th, Hua Shan bought 2,500 shares of Cerus stock. The stock was acquired at an average cost of $1.99 per share, with a total value of $4,975.00. Following the completion of the transaction, the director now directly owns 32,386 shares of the company's stock, valued at $64,448.14. Learn More on Hua Shan's trading history.
Who are Cerus' active insiders?: Cerus' insider roster includes Richard Benjamin (Chief Medical Officer), Eric Bjerkholt (Director), Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Jensen (Insider), Ann Lucena (Director), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), Hua Shan (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.
Are insiders buying or selling shares of Cerus?: In the last year, insiders at the biotechnology company sold shares 13 times. They sold a total of 461,150 shares worth more than $700,809.60. The most recent insider tranaction occured on March, 13th when COO Vivek K Jayaraman sold 29,985 shares worth more than $43,478.25. Insiders at Cerus own 5.6% of the company. Learn More about insider trades at Cerus.
Information on this page was last updated on 3/13/2025.

Hua Shan Insider Trading History at Cerus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/13/2024	Buy	2,500	$1.99	$4,975.00	32,386

Hua Shan Buying and Selling Activity at Cerus

Cerus Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Today's Range

Now: $2.10

$1.96

$2.11

50 Day Range

MA: $1.60

$1.40

$2.10

2 Week Range

Now: $2.10

$1.12

$2.24

Volume

1,534,120 shs

Average Volume

1,403,832 shs

Market Capitalization

$403.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55